Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2019/054803, filed Oct 4, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,535,618 | Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | ||
| US 11,814,386 | Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | ||
| Application 18/476,249 | Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors Abandoned Abandoned Dec 2, 2024 | Forma Therapeutics, Inc. | Abandoned | Abandoned Dec 2, 2024 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Forma Therapeutics, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.